AIMTB Enzyme-linked Immunosorbent Assay Platform
① Enhanced Sensitivity
This platform can detect both pulmonary and extrapulmonary tuberculosis cases with a detection rate exceeding 90% in tuberculosis patients.
② Superior Specificity
This platform effectively mitigates interference from the BCG vaccine and most non-tuberculous mycobacteria, ensuring high specificity in tuberculosis detection.
③ Streamlined Sampling Process
Simplifies the sampling procedure by utilizing whole blood, this approach eliminates the impact of the patient's bacterial load or the stage of infection, ensuring consistent and reliable test results.
④ Swift and Efficient Detection
Results available within 24 hours, this platform eliminates the need for repeated visits.
AIMTB (FLF, Fluorescence Lateral Flow)
① Outstanding Performance
The AIMTB Fluorescence Immunochromatography Platform delivers exceptional performance with a sensitivity range of 85%-95% and a specificity range of 93%-99%. It remains unaffected by interference from the BCG vaccine and most non-tuberculous mycobacteria, ensuring reliable and accurate results.
② Simplified Operation
Designed as a Point-of-Care Testing (POCT) platform, the AIMTB Fluorescence Immunochromatography Platform offers rapid detection, providing results within 15 minutes. This eliminates the need for repeated calibration and incorporates automatic result interpretation, simplifying the entire testing process.
③ Cost-Effective Solution
The platform's room temperature storage and transportation feature significantly reduces storage costs. Moreover, its straightforward operation minimizes labor costs, making it a cost-effective choice for tuberculosis diagnostics.